Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
E Kon, N Ad-El, I Hazan-Halevy… - Nature reviews clinical …, 2023 - nature.com
Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …
ongoing research area that started before these versatile nanoparticles were successfully …
Adoptive cellular therapies: the current landscape
MW Rohaan, S Wilgenhof, JBAG Haanen - Virchows Archiv, 2019 - Springer
For many cancer types, the immune system plays an essential role in their development and
growth. Based on these rather novel insights, immunotherapeutic strategies have been …
growth. Based on these rather novel insights, immunotherapeutic strategies have been …
NY-ESO-1 based immunotherapy of cancer: current perspectives
R Thomas, G Al-Khadairi, J Roelands… - Frontiers in …, 2018 - frontiersin.org
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response
PF Robbins, SH Kassim, TLN Tran, JS Crystal… - Clinical Cancer …, 2015 - AACR
Purpose: Although adoptive cell therapy can be highly effective for the treatment of patients
with melanoma, the application of this approach to the treatment of other solid tumors has …
with melanoma, the application of this approach to the treatment of other solid tumors has …
Improved survival with ipilimumab in patients with metastatic melanoma
FS Hodi, SJ O'day, DF McDermott… - … England Journal of …, 2010 - Mass Medical Soc
Background An improvement in overall survival among patients with metastatic melanoma
has been an elusive goal. In this phase 3 study, ipilimumab—which blocks cytotoxic T …
has been an elusive goal. In this phase 3 study, ipilimumab—which blocks cytotoxic T …
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
PF Robbins, RA Morgan, SA Feldman… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an
effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 …
effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 …
[HTML][HTML] Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Recent developments have set the stage for immunotherapy as a supplement to
conventional cancer treatment. Consequently, a significant effort is required to further …
conventional cancer treatment. Consequently, a significant effort is required to further …
[HTML][HTML] Autoantibody production in cancer—the humoral immune response toward autologous antigens in cancer patients
A link between autoimmune responses and cancer via autoantibodies was first described in
the 1950s. Since, autoantibodies have been studied for their potential use as cancer …
the 1950s. Since, autoantibodies have been studied for their potential use as cancer …
The MAGE protein family and cancer
The Melanoma Antigen Gene (MAGE) protein family is a large, highly conserved group of
proteins that share a common MAGE homology domain. Intriguingly, many MAGE proteins …
proteins that share a common MAGE homology domain. Intriguingly, many MAGE proteins …
A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma
SM Hiniker, SA Reddy, HT Maecker… - International Journal of …, 2016 - Elsevier
Purpose Local radiation therapy (RT) combined with systemic anti-cytotoxic T-lymphocyte–
associated protein-4 immunotherapy may enhance induction of systemic antimelanoma …
associated protein-4 immunotherapy may enhance induction of systemic antimelanoma …